Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
06/05/2024 | 08:00 | GlobeNewswire Inc. | Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca | NASDAQ:AZN | AstraZeneca PLC |
02/05/2024 | 13:00 | Business Wire | CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
01/05/2024 | 13:05 | Business Wire | AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio | NASDAQ:AZN | AstraZeneca PLC |
29/04/2024 | 13:00 | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow | NASDAQ:AZN | AstraZeneca PLC |
25/04/2024 | 14:00 | PR Newswire (US) | AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:AZN | AstraZeneca PLC |
25/04/2024 | 13:53 | IH Market News | U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast | NASDAQ:AZN | AstraZeneca PLC |
25/04/2024 | 13:52 | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NASDAQ:AZN | AstraZeneca PLC |
25/04/2024 | 08:00 | Business Wire | Q1 2024 results | NASDAQ:AZN | AstraZeneca PLC |
16/04/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
12/04/2024 | 13:05 | IH Market News | Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News | NASDAQ:AZN | AstraZeneca PLC |
11/04/2024 | 13:24 | IH Market News | Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News | NASDAQ:AZN | AstraZeneca PLC |
11/04/2024 | 13:00 | Business Wire | FASENRA approved for treatment of children aged 6 to 11 with severe asthma | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 05:10 | Business Wire | ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 03:43 | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors | NASDAQ:AZN | AstraZeneca PLC |
05/04/2024 | 13:00 | Business Wire | IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
02/04/2024 | 13:00 | Business Wire | Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer | NASDAQ:AZN | AstraZeneca PLC |
02/04/2024 | 08:00 | Business Wire | Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | NASDAQ:AZN | AstraZeneca PLC |
01/04/2024 | 13:00 | Business Wire | VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH | NASDAQ:AZN | AstraZeneca PLC |
27/03/2024 | 11:54 | IH Market News | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News | NASDAQ:AZN | AstraZeneca PLC |
26/03/2024 | 12:20 | IH Market News | Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News | NASDAQ:AZN | AstraZeneca PLC |
25/03/2024 | 12:00 | Business Wire | ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) | NASDAQ:AZN | AstraZeneca PLC |
19/03/2024 | 12:33 | IH Market News | Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More | NASDAQ:AZN | AstraZeneca PLC |
19/03/2024 | 12:00 | Business Wire | AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer | NASDAQ:AZN | AstraZeneca PLC |
19/03/2024 | 11:52 | IH Market News | AstraZeneca to acquire Fusion for $2 billion | NASDAQ:AZN | AstraZeneca PLC |
18/03/2024 | 12:00 | Business Wire | AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio | NASDAQ:AZN | AstraZeneca PLC |
14/03/2024 | 12:39 | IH Market News | Fisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase Initiative | NASDAQ:AZN | AstraZeneca PLC |
13/03/2024 | 12:06 | Business Wire | AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD | NASDAQ:AZN | AstraZeneca PLC |
07/03/2024 | 11:43 | IH Market News | Tesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak Forecast | NASDAQ:AZN | AstraZeneca PLC |
26/02/2024 | 22:05 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
26/02/2024 | 15:00 | PR Newswire (Canada) | Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign | NASDAQ:AZN | AstraZeneca PLC |